FLT3 inhibitor design using molecular docking based virtual screening for acute myeloid leukemia

Area of Science:

• Oncology
• Computational Chemistry
• Pharmacology

Background:

• Acute Myeloid Leukaemia (AML) is a significant blood cancer.
• Fms-like tyrosine kinase 3 (FLT3) is a key therapeutic target in AML, driving cancer cell proliferation.
• Existing FLT3 inhibitors like quizartinib have limitations.

Purpose of the Study:

• To identify novel compounds with enhanced inhibitory activity against FLT3 using virtual screening.
• To evaluate the potential of newly identified compounds as improved therapeutic agents for AML.

Main Methods:

• Molecular docking and virtual screening were employed to analyze potential FLT3 inhibitors.
• PubChem Compound IDs were used for compound identification and analysis.
• Comparative studies included drug-drug comparisons, ADMET predictions, and pharmacophore analysis.

Main Results:

• Quizartinib was identified as a top-scoring established FLT3 inhibitor.
• A novel compound (PubChem CID: 44598530) demonstrated higher affinity scores than quizartinib.
• In silico analyses confirmed the novel compound's potential as an efficient FLT3 inhibitor.

Conclusions:

• A novel compound exhibits superior predicted affinity for FLT3 compared to existing inhibitors.
• This compound represents a promising candidate for developing more effective AML treatments.
• Further research and experimental validation are warranted to confirm its therapeutic efficacy.